Addition of Mezigdomide to Standard Therapy Significantly Improves Outcomes in Relapsed Refractory Multiple Myeloma

For patients with relapsed or refractory multiple myeloma (RRMM), the addition of the oral drug mezigdomide to standard treatment with carfilzomib and dexamethasone markedly improved progression-free survival over standard treatment alone, according to results from a phase 3 clinical trial led by investigators at Dana-Farber Cancer Institute.

By
May 29, 2026
5 min

Dana-Farber

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

#1

Dana-Farber Cancer Institute

Boston, MA
Key Differentiators
- Hematology
- Oncology
#2

Harvard Medical School

Boston, MA
Key Differentiators
- Medicine
- Hematology
#3

Jerome Lipper Multiple Myeloma Center

Boston, MA
Key Differentiators
- Hematology
- Oncology
#4

Emory University School of Medicine

Atlanta, GA
Key Differentiators
- Hematology
- Oncology
#5

National and Kapodistrian University of Athens

Athens, Greece
Key Differentiators
- Hematology

Addition of Mezigdomide to Standard Therapy Significantly Improves Outcomes in Relapsed Refractory Multiple Myeloma

Top Institutions in Oncology

Dana-Farber Cancer Institute

Harvard Medical School

Jerome Lipper Multiple Myeloma Center

Emory University School of Medicine

National and Kapodistrian University of Athens

Original Source(s)

Addition of Mezigdomide to Standard Therapy Significantly Improves Outcomes in Relapsed Refractory Multiple Myeloma

Related Content

2026 AACR Renal Cell Carcinoma Highlights

Multimodal echocardiographic techniques in the diagnosis of cardiac tumors: applications and recent advances

Alectinib shows promise for the treatment of refractory ALK-positive large B-cell lymphoma: a case report